Table 1.

Impact of different doses of ezetimibe on liver mass and cholesterol content in mice with LAL deficiency.

Gender	Genotype	Approx. dose of ezetimibe (mg/ day/ kg body wt)	No. of mice	Body wt (g)	Liver wt (g)	Hepatic total cholesterol concentration (mg/ g)	Whole-liver cholesterol content (mg/ organ)
Male	Lal+/+	0	4	24.3 ± 1.3	1.33 ± 0.09	2.14 ± 0.06	2.83 ± 0.14
	Lal−/−	0	4	24.3 ± 0.5	2.41 ± 0.08	57.4 ± 3.3	138.5 ± 9.1
	Lal−/−	5	4	24.5 ± 1.1	2.29 ± 0.17	41.3 ± 2.5*	95.2 ± 10.3*
	Lal−/−	20	4	23.5 ± 1.2	1.95 ± 0.17*	37.3 ± 1.1*	72.5 ± 4.9*
Female	Lal+/+	0	6	20.9 ± 0.2	1.08 ± 0.03	2.45 ± 0.04	2.63 ± 0.04
	Lal−/−	0	6	21.3 ± 0.4	2.39 ± 0.09	59.1 ± 2.4	141.0 ± 7.7
	Lal−/−	40	6	18.8 ± 0.6*	1.70 ± 0.03*	46.2 ± 1.9*	78.4 ± 3.2*

All mice were weaned at 21 days and thereafter fed ad libitum a rodent cereal-based diet either alone or containing ezetimibe at different doses until 50 days of age.

Values are mean ± SEM for the number of mice indicated.

^*p<0.05 compared to the untreated Lal^−/− mice of the same gender.